HIVandHepatitis.com coverage of the 49th European Association for the Study of the Liver's International Liver Congress (EASL 2014) in London, April 9-13, 2014.
Conference highlights include new interferon-free treatments for hepatitis C, hepatitis B and delta, and management of liver disease complications such as cirrhosis and hepatocellular carcioma.
BMS-986001, an experimental HIV nucleoside reverse transcriptase inhibitor, was shown to be as effective as tenofovir with less bone loss, but more people who took it developed resistance, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC. Bristol-Myers Squibb has announced it will end its development of the drug.
The National Institutes of Health has awarded a $20 million grant to a consortium that will seek to develop an intravaginal ring that delivers antiretroviral drugs for prevention of HIV infection, the participating research institutions recently announced. The collaboration will test various combinations of antiretrovirals to determine which are most effective when delivered together for pre-exposure prophylaxis, or PrEP.
AbbVie's 3D hepatitis C regimen containing ABT-450, ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 SAPPHIRE trials, according to a pooled analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC. While most patients experienced some adverse events, serious side effects were rare and few people discontinued treatment early for this reason.